Scarica l'app Stockscreener
26.06
0.04%
0.010
Dopo l'orario di chiusura:
25.40
-0.66
-2.53%
Precedente Chiudi:
$26.05
Aprire:
$26.39
Volume 24 ore:
1.15M
Relative Volume:
0.94
Capitalizzazione di mercato:
$3.27B
Reddito:
$247.00M
Utile/perdita netta:
$-353.00M
Rapporto P/E:
-7.8963
EPS:
-3.3003
Flusso di cassa netto:
$-484.00M
1 W Prestazione:
+5.08%
1M Prestazione:
+13.50%
6M Prestazione:
+31.95%
1 anno Prestazione:
+191.50%
Intervallo 1D:
$25.25
$26.70
Intervallo di 1 settimana:
$23.91
$26.70
Portata 52W:
$7.06
$28.72
Arcus Biosciences Inc Stock (RCUS) Company Profile
Nome
Arcus Biosciences Inc
Settore
Industria
Telefono
(510) 694-6200
Indirizzo
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
26.06 | 3.27B | 247.00M | -353.00M | -484.00M | -3.3003 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-12 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-01-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Iniziato | H.C. Wainwright | Neutral |
| 2024-10-08 | Iniziato | Wells Fargo | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-11-23 | Iniziato | Evercore ISI | Outperform |
| 2020-04-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-09-27 | Iniziato | Mizuho | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2018-10-09 | Iniziato | Wedbush | Outperform |
| 2018-04-09 | Iniziato | Citigroup | Buy |
| 2018-04-09 | Iniziato | Goldman | Neutral |
| 2018-04-09 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
Arcus Biosciences, Inc. (RCUS) reports Q1 loss, beats revenue estimates - MSN
Arcus (RCUS) Q1 2026 Earnings Call Transcript - AOL.com
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: Arcus Biosciences Q1 2026 results miss expectations - Investing.com
Arcus Biosciences Q1 Loss Narrows, Revenue Falls - marketscreener.com
Earnings Flash (RCUS) Arcus Biosciences Posts Q1 EPS -$1.02, vs. FactSet Est of -$0.88 - marketscreener.com
Earnings Flash (RCUS) Arcus Biosciences, Inc. Reports Q1 Revenue $17.0M, vs. FactSet Est of $29.5M - marketscreener.com
Arcus Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Arcus Biosciences (RCUS) Q1 2026 loss widens amid Gilead shift and trial setback - Stock Titan
Arcus Biosciences (NYSE: RCUS) details Q1 loss, cash runway and trial shifts - Stock Titan
Arcus lines up 2026 kidney cancer trial milestones with $876M cash - Stock Titan
MSN Money - MSN
Arcus Biosciences in the spotlight: Earnings test casdatifan focus By Investing.com - Investing.com South Africa
Arcus Biosciences Inc (RCUS) Q1 2026: Everything You Need To Kno - GuruFocus
Understanding Momentum Shifts in (RCUS) - Stock Traders Daily
Is Trial Failures And Gilead Pullback Altering The Investment Case For Arcus Biosciences (RCUS)? - Sahm
Arcus Advances Quemliclustat With Completed Phase 1 Metabolism Study - TipRanks
What's going on with Arcus Biosciences stock on Wednesday? - MSN
Assessing Arcus Biosciences (RCUS) Valuation After STAR-121 Termination And Gilead Option Changes - Sahm
Arcus Biosciences, Inc. (RCUS) may report negative earnings: Know the trend ahead of next week's release - MSN
Arcus Biosciences (RCUS) to Release Quarterly Earnings on Tuesday - MarketBeat
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Arcus halts Gilead-partnered late-stage trial for lung cancer drug - MSN
Arcus Biosciences: TIGIT In The Rearview Mirror, But Market Pricing A Bit Too Aggressively For Now - Seeking Alpha
Arcus Biosciences (RCUS) Is Up 5.2% After Lung Trial Futility Results And Gilead Option Shift - Yahoo Finance
New Arcus hire gets 4,200 options and 2,100 RSUs under plan - Stock Titan
Arcus Biosciences Announces New Employment Inducement Grants - marketscreener.com
Arcus Biosciences (RCUS) moves 7.8% higher: Will this strength last? - MSN
Gilead’s Arcus Pullback and Idvynso HIV Challenge Might Change The Case For Investing In GILD - Yahoo Finance
RCUS insider files Form 144; plans to sell 53,826 shares (NYSE: RCUS) - Stock Titan
Arcus Biosciences stock hits 52-week high at 26.5 USD By Investing.com - Investing.com India
Arcus Biosciences (NYSE:RCUS) Hits New 1-Year HighShould You Buy? - MarketBeat
Avoiding Lag: Real-Time Signals in (RCUS) Movement - Stock Traders Daily
What's Going On With Arcus Biosciences Stock On Wednesday? - Benzinga
Arcus Biosciences (RCUS) Sees 12.2% Surge in Stock Price - GuruFocus
Arcus Biosciences stock hits 52-week high at 26.5 USD - Investing.com
Arcus Biosciences (NYSE:RCUS) Trading Up 12.7%Here's Why - MarketBeat
Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last? - Yahoo Finance
[ARS] Arcus Biosciences, Inc. SEC Filing - Stock Titan
Arcus Biosciences : to Host Conference Call to Discuss First-Quarter 2026 Financia... - marketscreener.com
Cancer drug developer Arcus sets May 5 webcast on Q1 results - Stock Titan
Arcus Biosciences (NYSE: RCUS) details 2026 virtual shareholder meeting votes - Stock Titan
Arcus Biosciences Inc Azioni (RCUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):